[1]
|
韩伟佳. 目前抗菌药临床应用中的某些问题与对策[J]. 中西医结合心血管病杂志, 2018, 6(8): 26-27.
|
[2]
|
Abbas, M., Paul, M. and Huttner, A. (2017) New and Improved? A Review of Novel Antibiotics for Gram-Positive Bacteria. Clinical Microbiology and Infection, 23, 697-703. https://doi.org/10.1016/j.cmi.2017.06.010
|
[3]
|
Cerceo, E., Deitelzweig, S.B., Sherman, B.M., et al. (2016) Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microbial Drug Resistance, 22, 412-431. https://doi.org/10.1089/mdr.2015.0220
|
[4]
|
Corcione, S., De, R. and Francesco, G. (2018) The Optimal Duration of Treatment for Skin and Soft Tissue Infections and Acute Bacterial Skin and Skin Structure Infections. Current Opinion in Infectious Diseases, 31, 155-162.
https://doi.org/10.1097/QCO.0000000000000440
|
[5]
|
Jindamwar, P., Roy, P., Chaudhary, C.N., et al. (2016) Novel Reporting of Community Acquired Methicillin Resistant Staphylococcus aureus (CA-MRSA) Strain at a Tertiary Care Centre. International Journal of Current Microbiology and Applied Sciences, 5, 555-564. https://doi.org/10.20546/ijcmas.2016.510.062
|
[6]
|
高红彦. 喹诺酮类抗菌药应用情况调查及合理用药分析[J]. 山东医学高等专科学校学报, 2017, 39(3): 221-223.
|
[7]
|
张磊, 毛东东, 陈秋. 2014-2016年平顶山市部分医院喹诺酮类抗菌药的应用分析[J]. 青岛医药卫生, 2018, 50(2): 109-112.
|
[8]
|
Pfaller, M.A., Sader, H.S., Rhomberg, P.R., et al. (2017) In Vitro Activity of Delafloxacin Againstcontemporary Bacterial Pathogens from the United States and Europe, 2014. Antimicrobial Agents and Chemotherapy, 61, e02609-16.
https://doi.org/10.1128/AAC.02609-16
|
[9]
|
Aldred, K.J., Kerns, R.J. and Osheroff, N. (2014) Mechanism of Quinolone Action and Resistance. Biochemistry, 53, 1565-1574. https://doi.org/10.1021/bi5000564
|
[10]
|
Bambeke, V.F. (2014) Renaissance of Antibiotics Against Difficult Infections: Focus on Oritavancin and New Ketolides and Quinolones. Annals of Medicine, 46, 512-529. https://doi.org/10.3109/07853890.2014.935470
|
[11]
|
毕煌垒, 张佳岳, 刘晓慧, 等. 新型广谱氟喹诺酮类抗菌药物——德拉沙星[J]. 临床药物治疗杂志, 2017, 15(7): 6-10.
|
[12]
|
Bambeke, V.F. (2015) Delafloxacin, A Non-Zwitterionic Fluoroquinolone in Phase III of Clinical Development: Evaluation of Its Pharmacology, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy. Future Microbiology, 10, 1111-1123. https://doi.org/10.2217/fmb.15.39
|
[13]
|
Bassetti, M., Della, S.P., Pecori, D., et al. (2015) Delafloxacin for the Treatment of Respiratory and Skin Infections. Expert Opinion on Investigational Drugs, 24, 433-442. https://doi.org/10.1517/13543784.2015.1005205
|
[14]
|
Bassetti, M., Vena, A., Carnelutti, A., et al. (2018) Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections: Focus on Intravenous Delafloxacin. Infection and Drug Resistance, 11, 479-488.
https://doi.org/10.2147/IDR.S142140
|
[15]
|
张建忠. 2017年6月FDA批准新药概况[J]. 上海医药, 2017, 38(15): 95.
|
[16]
|
王秀娟, 郭彦玲. 一种德拉沙星的制备方法[J]. 精细化工中间体, 2017, 47(1): 56-59.
|
[17]
|
Kocsis, B., Domokos, J. and Szabo, D. (2016) Chemical Structure and Pharmacokinetics of Novel Quinolone Agents Represented by Avarofloxacin, Delafloxacin, Fnafloxacin, Zabofloxacin and Nemonoxacin. Annals of Clinical Microbiology and Antimicrobials, 15, 34. https://doi.org/10.1186/s12941-016-0150-4
|
[18]
|
王亚娟. 氟喹诺酮药物结构改造与抗菌活性研究新进展[J]. 河北化工, 2011, 34(6): 12-18.
|
[19]
|
Cho, J.C., Crotty, M.P., White, B.P. and Worley, M.V. (2018) What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone. Pharmacotherapy, 38, 108-121. https://doi.org/10.1002/phar.2050
|
[20]
|
So, W., Crandon, J.L. and Nicolau, D.P. (2015) Effects or Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella penuemoniae. Journal of Urology, 194, 563-570.
|
[21]
|
Markham, A. (2017) Delafloxacin: First Global Approval. Drugs, 77, 1481-1486.
https://doi.org/10.1007/s40265-017-0790-5
|
[22]
|
McCurdy, S., Lawrence, L., Quintas, M., et al. (2017) In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Non-Susceptible S. aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Antimicrobial Agents and Chemotherapy, 61, e00772-17.
|
[23]
|
Hoover, R., Hunt, T., Benedict, M., et al. (2016) Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin after Single and Multiple Doses in Healthy Volunteers. Clinical Therapeutics, 38, 53-65.
https://doi.org/10.1016/j.clinthera.2015.11.019
|
[24]
|
McEwen, A., Lawrence, L., Hoover, R., et al. (2015) Disposition, Metabo-lism and Mass Balance of Delafloxacin in Healthy Human Volunteers Following Intravenous Administration. Xenobiotica, 45, 1054-1062.
https://doi.org/10.3109/00498254.2015.1042946
|
[25]
|
Hoover, R., Hunt, T., Benedict, M., et al. (2016) Single and Multiple As-cending-Dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age. Clinical Therapeutics, 38, 39-52. https://doi.org/10.1016/j.clinthera.2015.10.016
|
[26]
|
Hoover, R., Harry, A.J., Laura, L., et al. (2017) Delafloxacin Pharmacokinet-ics in Subjects with Varying Degrees of Renal Function. The Journal of Clinical Pharmacology, 58, 514-521.
|
[27]
|
Hoover, R., Mar-bury, T.C., Preston, R.A., et al. (2017) Clinical Pharmacology of Delafloxacin in Patients with Hepatic Impairment. The Journal of Clinical Pharmacology, 57, 328-335. https://doi.org/10.1002/jcph.817
|
[28]
|
Lepak, A.J. and Andes, D.R. (2016) In Vivo Phar-macodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae and Klebsiella pneumoni-ae in the Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 60, 4764-4769. https://doi.org/10.1128/AAC.00647-16
|
[29]
|
O’Riordan, W., Mehra, P., Manos, P., Kingsley, J., Lawrence, L. and Cammarata, S. (2015) A Randomized Phase 2 Study Comparing Two Doses of Delafloxacin with Tigecycline in Adults with Complicated Skin and Skin-Structure Infections. International Journal of Infectious Diseases, 30, 67-73. https://doi.org/10.1016/j.ijid.2014.10.009
|
[30]
|
Kingsley, J., Mehra, P., Lawrence, L.E., et al. (2016) A Randomized, Dou-ble-Blind, Phase 2 Study to Evaluate Subjective and Objective Outcomes in Patients with Acute Bacterial Skin and Skin Structure Infec-tions Treated with Delafloxacin, Linezolid or Vancomycin. Journal of Antimicrobial Chemotherapy, 71, 821-829.
https://doi.org/10.1093/jac/dkv411
|
[31]
|
Melinta Therapeutics. A Phase 3, Multicenter, Randomized, Double-Blind, Ac-tive-Controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared with Vancomycin plus Aztreonam in Patients with Acute Bacterial Skin and Skin Structure Infections. 2017-3-15/2018-5-25. https://clinicaltrials.gov/ct2/show/NCT01811732
|
[32]
|
Melinta Therapeutics. A Phase 3, Multicenter, Randomized, Double-Blind, Active Controlled Study to Evaluate the Efficacy and Safety of IV and Oral Delafloxacin Compared with Vancomycin plus Aztreonam in Patients with Acute Bacterial Skin and Skin Structure Infections.2017-3-15/2018-5-25. https://clinicaltrials.gov/ct2/show/NCT01984684
|
[33]
|
O’Riordan, W., Overcash, S., Lawrence, L., et al. (2017) Outcomes with IV/Oral Delafloxacin Compared to Vancomycin/Aztreonam in Treatment of Patients with Acute Bacterial Skin and Skin Structure In-fections (ABSSSI) and Gram-Negative Pathogens. Presented at: IDWeek; San Diego, CA, USA. Poster 1856.
|
[34]
|
Overcash, S., O’Riordan, W., Lawrence, L., et al. (2017) Outcomes with IV/Oral Delafloxacin Compared to Vancomycin/Aztreonam in Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Gram-Positive Pathogens. Presented at: IDWeek; San Diego, CA, USA. Poster 1857.
|
[35]
|
Bassetti, M., Pecori, D., Cojutti, P., Righi, E. and Pea, F. (2017) Clinical and Pharmacokinetic Drug Evaluation of Delafloxacin for the Treatment of Acute Bacterial Skin and Skin Structure Infections. Expert Opinion on Drug Me-tabolism & Toxicology, 13, 1193-1200. https://doi.org/10.1080/17425255.2017.1386654
|
[36]
|
Litwin, J.S., Benedict, M.S., Thorn, M.D., et al. (2015) A Thorough QT Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of Delafloxacin on Car-diac Repolarization. Antimicrobial Agents and Chemotherapy, 59, 3469-3473. https://doi.org/10.1128/AAC.04813-14
|
[37]
|
Ferguson, J., Lawrence, L., Paulson, S., Schlosser, M.J. and Cammarata, S. (2015) Assessment of Phototoxicity Potential of Delafloxacin in Healthy Male and Female Subjects: A Phase 1 Study. Poster Board Number F-1198A. 2015-09-17/2018-05-25. http://melinta.com/wp-content/uploads/2016/03/ICAAC15-Dela_phototoxicity_ph1.pdf
|
[38]
|
Red-grave, L.S., Sutton, S.B., Webber, M.A. and Piddock, L.J.V. (2014) Fluoroquinolone Resistance: Mechanisms, Impact on Bacteria, and Role in Evolutionary Success. Trends in Microbiology, 22, 438-445.
https://doi.org/10.1016/j.tim.2014.04.007
|
[39]
|
Remy, J.M., Tow-Keogh, C.A., McConnell, T.S., Dalton, J.M. and DeVito, J.A. (2012) Activity of Delafloxacin against Methicillin-Resistant Staphylococcus aureus: Resistance Selection and Characterization. Journal of Antimicrobial Chemotherapy, 67, 2814-2820. https://doi.org/10.1093/jac/dks307
|
[40]
|
巴合努拉∙赛提哈布勒. 研究氟喹诺酮类药物的不良反应及临床合理用药[J]. 世界最新医学信息文摘, 2018, 18(3): 90-91.
|